Company / R&D per Share
Terns Pharmaceuticals, Inc. R&D per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.88
FY2024
5-year range
$0.88 / $98.29
FY2020-FY2024
Trend
-1.0%
vs FY2023
Sector context
#149 of 204
Health Care
What the data says
At $0.88, Terns Pharmaceuticals, Inc.'s r&d per share ranks #149 of 204 in the Health Care sector. R&D per Share has declined for 4 consecutive years, from $98.29 in FY2020 to $0.88 in FY2024.
Based on SEC 10-K filings.
0.88 in FY2024 with a 3-year CAGR of -13.8%.
Declined from $1.10 to $0.88 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#149 of 204 in Health CareTop 73% of 204This company $0.88 Sector average $34.99
▼
-97.5% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s r&d per share has declined for 4 consecutive years.
- In FY2024, r&d per share decreased 1.0% year-over-year.
- Ranks #149 out of 204 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.88 | -1.0% |
| FY2023 | $0.89 | -19.0% |
| FY2022 | $1.10 | -20.3% |
| FY2021 | $1.38 | -98.6% |
| FY2020 | $98.29 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026